Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial Amarin Corporation plc , a clinical-stage biopharmaceutical organization with a focus on cardiovascular disease, announced that its MARINE trial today, a Stage 3 clinical trial of AMR101, has completed patient randomization and enrollment in to the treatment phase of the trial. THE BUSINESS indicated that top collection results from this trial are anticipated early in 2011, towards the early section of the range of assistance supplied previously. The MARINE trial is normally a multi-center, placebo-managed, randomized, double-blind, 12-week pivotal study to judge the efficacy and protection of 2 grams and 4 grams of AMR101 in individuals with fasting triglyceride amounts greater than or equal to 500 mg/dl http://markdunecforcongress.com/cialis-dosering/ .
Amenorrhea Causes Amenorrhea can result due to an abnormality in the hypothalamic-pituitary-ovarian axis, anatomical abnormalities of the genital system, or functional causes. Hypothalamic causes Craniopharyngioma Teratoma Sarcoidosis Kallmann syndrome Nutritional deficiency Low body weight or development delay Pituitary causes Prolactinemia – possibly caused by prolactinoma Other pituitary tumors Postpartum pituitary necrosis Autoimmune hypophysitis Pituitary radiation Sarcoidosis Ovarian causes Anovulation Hyperandrogenemia Polycystic ovary syndrome Premature ovarian failure Turner syndrome Pure gonadal dysgenesis Autoimmune oophoritis Fragile X premutation Radiation or chemotherapy galactose Anatomical abnormalities of the genital tract Intrauterine adhesions Imperforate hymen Transverse vaginal septum Aplasia of the vagina, the cervix, or the uterus Functional causes Anorexia/bulimia Chronic diseases Excessive excess weight gain or weight loss Malnutrition Depression or various other psychiatric disorders Recreational drug abuse Psychotropic drug use Excessive stress Excessive exercise Routine suppression with systemic hormonal contraceptive pills..